Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1

2025/09/16 by Giuseppe Ranieri, Andrea Lapucci, Giuseppe Orsomando +3
Medicine · Biochemistry, Genetics and Molecular Biology · #Sirtuins and Resveratrol in Medicine #Autophagy in Disease and Therapy #Calcium signaling and nucleotide metabolism

paper · pdf · doi:10.1002/1873-3468.70169

Abstract

In a previous study, we showed that the NAD antimetabolite Vacor is metabolized by two enzymes implicated in the NAD salvage pathway-to Vacor mononucleotide (VMN) by nicotinamide phosphoribosyltransferase (NAMPT) and, in turn, to Vacor adenine dinucleotide (VAD) by nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2)-leading to NAD depletion and antitumor activity. Recent findings in neurons show that VMN activates SARM1, a NAD glycohydrolase, triggering NAD depletion and degeneration. In this study, we report that altering NMNAT2 levels did not affect Vacor-induced NAD depletion or cell death. In contrast, SARM1 expression alone was sufficient to induce Vacor sensitivity. Further, we report that cancer cells sense the abnormal expression of SARM1 and readily induce the expression of NMNAT2. Overall, the data underscore the antitumor potential of pharmacological approaches aimed at activating SARM1.

Related

• Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms
• Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection
• Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice
• Regulation of Stem Cell Function by NAD +
• NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis